Yaqin Wang

ORCID: 0000-0003-1927-5840

Also affiliated with Royal Victoria Infirmary, Novartis (United States)

Immunology and MicrobiologyMedicineChemistry

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 2 papers. Top paper: “Alternative Complement Pathway Inhibition With Iptacopan for the Treatment of C3 Glomerulopathy-Study Design of the APPEAR-C3G Trial”.

Alternative Complement Pathway Inhibition With Iptacopan for the Treatment of C3 Glomerulopathy-Study Design of the APPEAR-C3G Trial

Kidney International Reports(2022)10.1016/j.ekir.2022.07.004

N/A

0DataRank · unranked

77 citations

David Kavanagh, Marina Vivarelli, Matthias Meier, Yaqin Wang, Nicholas J.A. Webb +3 more

Fine-tuning of the CRWN2-NTL9 module to repress PR1 expression by a viral effector during geminivirus infection

Fundamental Research(2026)10.1016/j.fmre.2025.06.003

N/A

0DataRank · unranked

0 citations

Yaqin Wang, Fangfang Li, Yuzhen Mei, Xueping Zhou, Chenlu Su